Get started
Author

Katarzyna Bazydło‐Guzenda

Observed names: Bazydlo-Guzenda, Katarzyna, Bazydło-Guzenda, Katarzyna, KATARZYNA BAZYDLO, KATARZYNA BAZYDLO-GUZENDA, Katarzyna Bazydlo-Guzenda, Katarzyna Bazydło, Katarzyna Bazydło-Guzenda
ORCID: 0000-0002-7970-3926
Observed ORCID: 0000-0002-7970-3926
OpenAlex ID: A5007778094
Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines
2018 · Rafał Moszczyński-Pętkowski, Jakub Majer, et al. · European Journal of Medicinal Chemistry · 30
Discovery and development of CPL207280 as new GPR40/FFA1 agonist
2021 · Mateusz Mach, Katarzyna Bazydło-Guzenda, et al. · European Journal of Medicinal Chemistry · 15
CPL207280, a Novel G Protein–Coupled Receptor 40/Free Fatty Acid Receptor 1–Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals
2021 · Katarzyna Bazydlo-Guzenda, Pawel Buda, et al. · Molecular Pharmacology · 13
PDF
Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey
2021 · Katarzyna Bazydlo-Guzenda, Pawel Buda, et al. · PLoS ONE · 8
PDF
First‐in‐human study of CPL207280 , a novel G‐protein‐coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration
2024 · Katarzyna Bazydło‐Guzenda, Katarzyna Jarus‐Dziedzic, et al. · Diabetes Obesity and Metabolism · 5
PDF
Chemical Composition and Antioxidant Activity of Cirsium vulgare Inflorescences
2017 · Jolanta Nazaruk, Sebastian Chłędzik, et al. · Natural Product Communications · 5
761-P: Safety and Pharmacokinetic Study of GPR40 Agonist (CPL207280) after a Single Dose in Healthy Subjects
2021 · KATARZYNA BAZYDLO-GUZENDA, AGNIESZKA GIERCZAK-PACHULSKA, et al. · Diabetes · 4
Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes
2026 · Aleksandra A. Czyrek, Daniel Krowarsch, et al. · Molecular Biomedicine · 2
PDF
2333-PUB: CPL207-280, a Potent and Safe GPR40 Agonist for the treatment of Type 2 Diabetes
2019 · KATARZYNA BAZYDLO-GUZENDA, PAWEL BUDA, et al. · Diabetes · 2
CCDC 2076005: Experimental Crystal Structure Determination
2021 · Mach, Mateusz, Bazydło-Guzenda, Katarzyna, et al. · The Cambridge Structural Database · 1
Discovery of CPL207-280CA, an Effective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes
2018 · KATARZYNA BAZYDLO, PAWEL BUDA, et al. · Diabetes · 1
Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes - raw data
2026 · Czyrek, Aleksandra, Krowarsch, Daniel, et al. · Uniwersytet Wrocławski
Works count: 12
Citation count: 86
H-index: 5
I10-index: 3
Year
Topic
Type